Update on the Pharmacologic Agents for Dyslipidemia / 임상당뇨병
Journal of Korean Diabetes
;
: 269-275, 2015.
Article
in Korean
| WPRIM
| ID: wpr-726852
ABSTRACT
Although statins have demonstrated consistent and strong effects on cardiovascular prevention, non-statin drugs have failed to show additional clinical benefit. Consequently, statins are currently recommended as first-line therapy in dyslipidemia. On the contrary, non-statin drugs are indicated in limited cases in which statins are not sufficiently effective or intolerable. A recent trial on ezetimibe provides evidence supporting further prescription of this agent. Proprotein convertase subtilisin-kexin type 9 inhibitors have strong low-density lipoprotein-cholesterol-lowering effects and were just approved in Western countries. However, results of clinical outcomes are not yet available. Other non-statin lipid-modifying agents have their own roles and limitations. Thus, it is important to have correct knowledge on these agents for optimal treatment of dyslipidemic patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Fatty Acids, Omega-3
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Proprotein Convertases
/
Dyslipidemias
/
Cholesterol Ester Transfer Proteins
/
Prescriptions
/
Fibric Acids
/
Ezetimibe
/
Niacin
Limits:
Humans
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS